Psyence Biomed
Psyence Biomedical Ltd. (NASDAQ:PBM) is a Nasdaq-listed company with its subsidiary, The Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in Neuroplastogens-based therapeutics, the manufacture of pharmaceutical-grade drug candidates and conducting Clinical Trials. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived Neuroplastogens treatments across a range of mental health disorders.
Psyence Biomed
The world’s first life science biotechnology company traded on the Nasdaq (NASDAQ:PBM) focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.
Our
Mission
Pioneering the use of natural
psychedelics for mental health
We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Leading the Business of Medicine and Science
Working at the intersection of medicine, commerce, and science, our physician-led company is headed by R+D leader CEO Dr. Neil Maresky, MD. Our expertise in intellectual property and capital markets and business development brings a global track record of sustainable growth and shareholder value.
Leading the Business of Medicine and Science
Working at the intersection of medicine, commerce, and science, our physician-led company is headed by R+D leader CEO Dr. Neil Maresky, MD. Our expertise in intellectual property and capital markets and business development brings a global track record of sustainable growth and shareholder value.
Our News
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
Our News
Psyence BioMed Announces Strategic Ibogaine Investment
Psyence BioMed has agreed to invest up to US$5 million in PsyLabs and pursue a share exchange to support manufacturing and development for its planned US ibogaine program. A potential Texas clinical trial remains under evaluation.
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Psyence BioMed welcomes renewed federal support for ibogaine development and outlines how its pharmaceutical manufacturing platform can contribute to responsible clinical research in the United States.